GlassScriptPhysician profile
Priscilla M Mann
NPI 1528597838
$2,879.42
in general payments reported to CMS, 2019-2025
14 companies · $647 in 2025
The $647 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $597 · 2023: $581 · 2024: $685 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $793.14 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $432.90 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.69 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $289.43 | 2021-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $232.51 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $221.16 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Sumitomo Pharma America, INC. | $106.15 | 2024-2025 | Gemtesa |
| Amgen INC. | $100.19 | 2023-2024 | Repatha, Evenity, Prolia |
| Amarin Pharma, INC. | $96.83 | 2021-2022 | |
| Pfizer INC. | $83.21 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $69.76 | 2022-2023 | Spravato, Xarelto |
| Exact Sciences Corporation | $38.08 | 2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $14.44 | 2021 | |
| Medtronic, INC. | $12.93 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.